Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00222 ...
Drug Name Glimepiride
Molecular Weight 490.62
Molecular Formula C24H34N4O5S
CAS Number 93479-97-1
SMILES CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O
External Links
DRUGBANK DB00222
PubChem Compound 3476
PDR 1031
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Melting Point 207.0 ℃ 207 ℃ MSDS

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Absorption 100.0 % ~100 % PO, oral; DRUGBANK
Bioavailability 100.0 % 100.0 % PO, oral; DRUGBANK
Bioavailability 100.0 % ~100 % PO, oral; The Pharmacological Basis of Therapeutics
C Max 359.0 ng/ml 359±98 ng/ml Oral single dose; The Pharmacological Basis of Therapeutics
T Max 2.5 h 2-3 h Oral single dose; normal,healthy; DRUGBANK
T Max 2.5 h 2-3 h Oral multiple dose; diabetes; DRUGBANK
T Max 2.5 h 2-3 h Oral single dose; The Pharmacological Basis of Therapeutics
Clearance 3.1 L/h 52.1±16.0 ml/min Total clearance; DRUGBANK
Clearance 2.9 L/h 48.5±29.3 ml/min Total clearance; Oral single dose; diabetes; patients; DRUGBANK
Clearance 3.2 L/h 52.7±40.3 ml/min Total clearance; Oral multiple dose; diabetes; patients; DRUGBANK
Clearance 2.9 L/h 47.8 ml/min Total clearance; intravenous injection, IV; normal,healthy; DRUGBANK
Clearance 0.0372 L/h/kg 0.62±0.26 ml/min/kg severe renal function ↑ ; The Pharmacological Basis of Therapeutics
Clearance 0.0300 L/h/kg 0.5 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 8.8 L 8.8 L intravenous injection, IV; normal,healthy; DRUGBANK
Volume of Distribution 0.18 L/kg 0.18 L/kg severe renal function ↑ ; The Pharmacological Basis of Therapeutics
Volume of Distribution 0.19 L/kg 0.19 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 6.5 h ~5-8 h elimination half-life; DRUGBANK
Half-life 3.4 h 3.4±2.0 h normal,healthy; Male, men; moderate renal function → ;severe renal function → ; The Pharmacological Basis of Therapeutics
Half-life 10.0 h 10 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 10000.0 mg/kg >10000 mg/kg PO, oral; Rattus, Rat; DRUGBANK
Toxicity LD50 3950.0 mg/kg 3950.0 mg/kg Intraperitoneal, IP; Rattus, Rat; DRUGBANK
Eliminate Route 60.0 % ~60 % Urinary excretion; PO, oral; Male, men; normal,healthy; DRUGBANK
Eliminate Route 40.0 % ~40 % Faeces excretion; PO, oral; Male, men; normal,healthy; DRUGBANK
Eliminate Route 0.50 % <0.5 % Urinary excretion; Male, men; normal,healthy; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 99.5 % >99.5 % plasma proteins; DRUGBANK
Protein Binding 99.5 % >99.5 % Male, men; normal,healthy; human, homo sapiens; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for children 8.0 mg/day 8 mg/day PO, oral Amaryl glimepiride PDR
Max dose for adolescents 8.0 mg/day 8 mg/day PO, oral Amaryl glimepiride PDR
Max dose for adults 8.0 mg/day 8 mg/day PO, oral Amaryl glimepiride PDR
Max dose for geriatric 8.0 mg/day 8 mg/day PO, oral Amaryl glimepiride PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1